Most Popular Articles : Pharmacogenetics and Genomics

Secondary Logo

Journal Logo

Most Popular Articles

ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19

Möhlendick, Birte; Schönfelder, Kristina; Breuckmann, Katharina; More

Pharmacogenetics and Genomics. 31(8):165-171, October 2021.

Implementation of pharmacogenomics into inpatient general medicine

Chen, Thomas; O’Donnell, Peter H.; Middlestadt, Merisa; More

Pharmacogenetics and Genomics. 33(2):19-23, February 2023.

Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting

Hall-Flavin, Daniel K.; Winner, Joel G.; Allen, Josiah D.; More

Pharmacogenetics and Genomics. 23(10):535-548, October 2013.

Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study

van der Wouden, Cathelijne H.; Böhringer, Stefan; Cecchin, Erika; More

Pharmacogenetics and Genomics. 30(6):131-144, August 2020.

Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis

Zuo, Xiao-cong; Ng, Chee M.; Barrett, Jeffrey S.; More

Pharmacogenetics and Genomics. 23(5):251-261, May 2013.

Association of morphine-induced antinociception with variations in the 5′ flanking and 3′ untranslated regions of the μ opioid receptor gene in 10 inbred mouse strains

Shigeta, Yoshihiro; Kasai, Shinya; Han, Wenhua; More

Pharmacogenetics and Genomics. 18(11):927-936, November 2008.

Association study of genetic variants in PLA2G4A, PLCG1, LAT, SYK, and TNFRS11A genes in NSAIDs-induced urticaria and/or angioedema patients

Ayuso, Pedro; Plaza-Serón, María del Carmen; Doña, Inmaculada; More

Pharmacogenetics and Genomics. 25(12):618-621, December 2015.

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28

Minami, Hironobu; Sai, Kimie; Saeki, Mayumi; More

Pharmacogenetics and Genomics. 17(7):497-504, July 2007.

Pharmacogenetic analysis of canonical versus noncanonical pathway of NF-kB in Crohn’s disease patients under anti-tumor necrosis factor-α treatment

Stavrou, Eleana F.; Chatzopoulou, Fani; Antonatos, Charalabos; More

Pharmacogenetics and Genomics. 32(6):235-241, August 2022.

A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs

Lonjou, Christine; Borot, Nicolas; Sekula, Peggy; More

Pharmacogenetics and Genomics. 18(2):99-107, February 2008.

The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study

de Keyser, Catherine E.; Peters, Bas J.M.; Becker, Matthijs L.; More

Pharmacogenetics and Genomics. 24(1):43-51, January 2014.

Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions

Kongpan, Thachanan; Mahasirimongkol, Surakameth; Konyoung, Parinya; More

Pharmacogenetics and Genomics. 25(8):402-411, August 2015.

The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia

Oosterom, Natanja; Berrevoets, Marijn; den Hoed, Marissa A.H.; More

Pharmacogenetics and Genomics. 28(10):223-229, October 2018.

Beta2-adrenergic receptor polymorphisms as a determinant of preferential bronchodilator responses to β2-agonist and anticholinergic agents in Japanese patients with chronic obstructive pulmonary disease

Konno, Satoshi; Makita, Hironi; Hasegawa, Masaru; More

Pharmacogenetics and Genomics. 21(11):687-693, November 2011.

Copy number variation in ALOX5 and PTGER1 is associated with NSAIDs-induced urticaria and/or angioedema

Plaza-Serón, María del Carmen; Ayuso, Pedro; Pérez-Sánchez, Natalia; More

Pharmacogenetics and Genomics. 26(6):280-287, June 2016.

The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation

Lloberas, Nuria; Elens, Laure; Llaudó, Ines; More

Pharmacogenetics and Genomics. 27(9):313-322, September 2017.

Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia

Megías-Vericat, Juan Eduardo; Martínez-Cuadrón, David; Herrero, María José; More

Pharmacogenetics and Genomics. 31(6):133-139, August 2021.

International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing

Pereira, Naveen L.; So, Derek; Bae, Jang-Ho; More

Pharmacogenetics and Genomics. 29(4):76-83, June 2019.

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions

Hung, Shuen-Iu; Chung, Wen-Hung; Jee, Shiou-Hwa; More

Pharmacogenetics and Genomics. 16(4):297-306, April 2006.

Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver

Girard, Hugo; Court, Michael H; Bernard, Olivier; More

Pharmacogenetics. 14(8):501-515, August 2004.

Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population

Tassaneeyakul, Wichittra; Jantararoungtong, Thawinee; Chen, Pei; More

Pharmacogenetics and Genomics. 19(9):704-709, September 2009.

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

Takahashi, Harumi; Wilkinson, Grant R.; Nutescu, Edith A.; More

Pharmacogenetics and Genomics. 16(2):101-110, February 2006.

NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis

Suvichapanich, Supharat; Fukunaga, Koya; Zahroh, Hilyatuz; More

Pharmacogenetics and Genomics. 28(7):167-176, July 2018.

Platinum pathway

Marsh, Sharon; McLeod, Howard; Dolan, Eileen; More

Pharmacogenetics and Genomics. 19(7):563-564, July 2009.

CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case–control study

Figueiras, Adolfo; Estany-Gestal, Ana; Aguirre, Carmelo; More

Pharmacogenetics and Genomics. 26(2):66-73, February 2016.

Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis

Haas, David W.; Mngqibisa, Rosie; Francis, Jose; More

Pharmacogenetics and Genomics. 32(1):24-30, January 2022.

Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice

Sychev, Dmitry Alekseevitch; Sokolov, Aleksey Vladimirovich; Reshetko, Olga Vilorovna; More

Pharmacogenetics and Genomics. 32(9):301-307, December 2022.

Very important pharmacogene summary ADRB2

Litonjua, Augusto A.; Gong, Li; Duan, Qing Ling; More

Pharmacogenetics and Genomics. 20(1):64-69, January 2010.

Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment

Donnelly, Louise A.; van Zuydam, Natalie R.; Zhou, Kaixin; More

Pharmacogenetics and Genomics. 23(10):518-525, October 2013.

Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis

Nishimura, Miki; Ueda, Mikito; Saruwatari, Junji; More

Pharmacogenetics and Genomics. 26(9):403-413, September 2016.

Clopidogrel pathway

Sangkuhl, Katrin; Klein, Teri E.; Altman, Russ B.

Pharmacogenetics and Genomics. 20(7):463-465, July 2010.